Gastrointestinal side effects comparison Retatrutide has a notably higher GI side effect burden at maximum doses
Experience potential weight reduction of up to 20% body weight with this innovative, once-weekly GIP/GLP-1 medicationtailored specifically to your needs
STEP-1 Trial (Semaglutide 2.4 mg, N=1,961) The STEP-1 trial published in the New England Journal of Medicine reported that among participants receiving semaglutide 2.4 mg subcutaneously once weekly, nausea occurred in 44.2%, diarrhea in 29.7%, vomiting in 24.5%, and constipation in 24.1%, compared to 16.0%, 15.9%, 6.8%, and 11.1% with placebo, respectively [3]
PMC 8078644
However, not everyone has the ability to detect when a vitamin, nutrient, or hormone deficiency is affecting their health